



### Product Description

Phoenix Auto is designed to target autoimmune diseases, specifically including rheumatoid arthritis, crohns disease and psoriasis. Developed to deliver pain management, reduce inflammation and better regulate the bodys own autoimmune system. Management, without compromising natural autoimmune functions.

### Cannabinoid Extract Proprietary Compound

CANNABIDIOL (CBD), TETRAHYDRACANNABINOL (THC), AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE, LINALOOL , P-CYMENE

### Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

### Global Distribution Strategy

Phoenix Auto is classified as a specific formulation and dosation product that may be exempted or scheduled under a specific country regulations governing pharmaceuticals and drug control. The product must be produced, distributed and sold through licensed medical cannabis facilities and pharmaceutical distribution licensed to handle tetrahydracannabinol. Distribution will be from Vanuatu and state to state US manufacturing.

<p><b>Online</b></p> <p>This product is classified as containing high amounts of "THC from Cannabis" and therefore can only be sold through licensed agencies. Phoenix Auto online ordering a provides for pick-up from a licensed distributor. Sold as Phoenix Auto (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.</p>	<p> <b>Australia</b></p> <p>Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2024.</p>	<p> <b>Europe</b></p> <p>Partner with local licensed distributor under medical cannabis laws. Local clinical trials to be completed in 2025.</p>
<p><b>Global Distribution</b></p> <p>Now that 47 countries have legalized medical cannabis, the intercountry trade is starting to expand. Phoenix Life is focused on import and export of all of its products from company owned and partnered production facilities. Phoenix Auto can only be sold through licensed agencies through local production and export to over 40 countries.</p>	<p> <b>United States</b></p> <p>State to state distribution under product licensing agreement with Equaliti. Clinical trials to be commenced late 2025.</p>	<p> <b>Vanuatu</b></p> <p>May be supplied under Dr Approval. Local Supply expected in 2022.</p>

### Medical History and Development Information

Initial Studies with a group of cannabis and non-cannabis users stated that the generally experience reduction in symptoms, including rhumatiod arthritis, colitis, crohn’s disease, psoriasis and other triggers of cytokine storms associated with autoimmune responses. The product is designed to be sold in Soft Gel Capsules and Sublingual Sprays.

### Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND  Completed  Next Step  Not Completed

### Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at <https://pubmed.ncbi.nlm.nih.gov/32017684/> 2020 Jan 30;11(1):e0007. DOI: 10.5041/RMMJ.10389 PMID: 32017684 PMCID: PMC7000161 Author(s): Tal Gonen , Howard Amital

#### Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases

Abstract: Chronic pain is a common complaint among patients, and rheumatic diseases are a common cause for chronic pain. Current pharmacological interventions for chronic pain are not always useful or safe enough for long-term use. Cannabis and cannabinoids are currently being studied due to their potential as analgesics. In this review we will discuss current literature regarding cannabinoids and cannabis as treatment for rheumatic diseases. Fibromyalgia is a prevalent rheumatic disease that causes diffuse pain, fatigue, and sleep disturbances. Treatment of this syndrome is symptomatic, and it has been suggested that cannabis and cannabinoids could potentially alleviate some of the symptoms associated with fibromyalgia. In this review we cite some of the evidence that supports this claim. Cannabinoids and cannabis are commonly investigated as analgesic agents, but in recent years more evidence has accumulated on their potential immune-modulatory effect, supported by results in animal models of certain rheumatic diseases. While results that demonstrate the same effect in humans are still lacking, cannabinoids and cannabis remain potential drugs to alleviate the pain associated with rheumatic diseases, as they were shown to be safe and to cause limited adverse effects.